サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179871

乳房自動超音波装置（ABUS）の世界市場-2023-2030

Global Automated Breast Ultrasound Systems (ABUS) Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
乳房自動超音波装置（ABUS）の世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

乳房自動超音波装置の世界市場規模は、2023年に14億2,400万米ドル、2030年には24億5,200万米ドルに達し、予測期間（2023～2030年）にCAGR12.4％で成長すると予測されています。

より一般的な技術である乳房自動超音波装置（ABUS）は、乳房組織が緻密（脂肪よりも腺や繊維が多い）な女性において、それが唯一の余分な危険因子であっても、最大で30％多く腫瘍を検出することができます。乳房の密度が高い女性は、マンモグラフィーでは不十分な場合があり、ABUSを採用することでより多くの悪性腫瘍を発見することができます。超音波検査中に電離放射線を使用することはなく、ABUSは高密度乳房を撮影するための迅速、無痛、効率的なアプローチです。

市場力学

乳房自動超音波装置の世界市場を牽引する主な要因乳房自動超音波装置の技術的進歩や乳がんに関する意識の高まりが政府の取り組みに有利に働くため、世界の乳がん罹患率の上昇が市場の最も大きな促進要因となっています。

世界の乳がんの有病率の上昇は、市場の最も重要な促進要因となっています。

WHOによると、乳房の腺組織において、乳がんは乳管（85％）または小葉（15％）の生きた細胞（上皮）で始まります。悪性化は当初、乳管または小葉に限定され、多くの場合、症状を示さず、転移のリスクも低いとされています。2020年には世界で684,000人が乳がんのために死亡し、230万人の女性が罹患しています。2020年末時点で世界で最も多いがんは乳がんで、過去5年間に780万人の女性が診断されました。乳がんは、世界的に女性の障害調整生命年（DALY）の損失が最も多いがんの一種です。乳がんは、世界のすべての国で、思春期以降のどの年齢の女性にも発生しますが、晩年になるほど発生率が高くなります。

米国がん協会では、2022年には、女性の浸潤性乳がんの新規症例が約287,840例、乳管内がん（DCIS）の新規症例が約51,400例、女性の乳がん関連死亡が約43,250例となると予測しています。乳がんは、中年以降の女性に多くみられます。乳がんの診断時の典型的な年齢は62歳です。したがって、女性の乳がんが発見される平均年齢は62歳以下となります。45歳以下の女性で乳がんと診断されることは、驚くほどまれなことです。

乳房自動超音波装置の価格が高いことが市場成長の妨げになります。

自動乳房超音波画像診断システムのアプリケーションは、多くの国で厳しい規則によって制約を受けています。さらに、従来のがんスクリーニング方法と比較して、自動乳房超音波システム（ABUS）のコストが高いことが、市場拡大を抑制すると予想されます。

COVID-19の影響分析

感染症の頻度は、COVID-19の大流行が始まると、その深刻さと蔓延の速度が増加しました。世界のパンデミックの初期に、COVID-19ウイルスに感染した患者の数が増加しました。異なる感染経路を減少させ、コントロールするために、病院は最優先事項として緊急プロトコルを採用しました。そのため、超音波スクリーニングが必要な選択的手術は減少しました。選択的超音波治療が減少したにもかかわらず、画像サービスを必要とする緊急処置のためのX線、CTスキャン、超音波の使用は増加しました。COVID-19の長期的な影響により、腎臓や肺を中心とした特殊な診断のために超音波診断装置の導入が増加すると予想されます。肺の超音波検査件数は、パンデミックの初期に増加傾向を示しました。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 乳房自動超音波装置の技術的進歩の増加
      • 乳がんに関する意識の高まりと政府の積極的な取り組み
    • 抑制要因
      • 乳房自動超音波装置の高価格化
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • プライシング分析
  • 規制分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的取り組み
  • まとめ

第7章 超音波タイプ別

  • ドップラー超音波
  • カラードップラー
  • 経腟超音波検査

第8章 アプリケーション別

  • 乳房画像診断
  • スクリーニング

第9章 エンドユーザー別

  • 病院
  • 画像診断センター
  • 診断ラボ

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第11章 競合情勢

  • 主な展開と戦略
  • 企業シェア分析
  • 製品ベンチマーク
  • 注目の主要企業リスト

第12章 企業プロファイル

  • General Healthcare Company
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Hitachi, Ltd
  • Koninklijke Philips N.V.
  • Siemens AG
  • SonoCine Inc
  • Qview Medical
  • Koios Medical
  • Volpara Solutions Limited
  • Delphinus Medical Technologies, Inc.
  • Nova Medical Inc

第13章 乳房自動超音波装置の世界市場-DataM

目次
Product Code: DMMD914

Market Overview

The global automated breast ultrasound systems market size was valued at US$ 14,24 million in 2023 and is estimated to reach US$ 2452 million by 2030, growing at a CAGR of 12.4% during the forecast period (2023-2030).

A more popular technique, Automated Breast Ultrasound (ABUS), can detect up to 30% more tumors in women with dense breast tissue (more glandular or fibrous than fatty), even if it is the only extra risk factor. Women with denser breasts may make mammography insufficient and can employ ABUS to discover more malignancies. No ionizing radiation is used during ultrasound procedures, and ABUS is a quick, painless, and efficient approach to photographing dense breasts.

Market Dynamics

The major factors driving the global Automated breast ultrasound systems market rising prevalence of breast cancer worldwide is the most significant driving factor of the market, as increasing technological advancements in automated breast ultrasound systems and rising awareness regarding breast cancer favorable government initiatives.

The rising prevalence of breast cancer worldwide is the most significant driving factor in the market.

According to WHO, in the glandular tissue of the breast, breast cancer begins in the living cells (epithelium) of the ducts (85%) or lobules (15%). The malignant development is initially restricted to the duct or lobule, where it often exhibits no symptoms and has a low risk of spreading. 684,000 people worldwide died in 2020 due to breast cancer, which affected 2.3 million women. The most common cancer globally as of the end of 2020 was breast cancer, diagnosed in 7.8 million women in the previous five years. Breast cancer is the form of cancer that results in the most lost disability-adjusted life years (DALYs) for women globally. Breast cancer occurs in every nation of the world in women at any age after puberty but with rising rates in later life.

The American Cancer Society predicts that in 2022, there will be about 287,840 new cases of invasive breast cancer in women, about 51,400 new instances of ductal carcinoma in situ (DCIS), and about 43,250 new cases of breast cancer-related deaths in women. Breast cancer is more common in women in their middle years and older. The typical age at breast cancer diagnosis is 62 years old. The average age at which breast cancer in women is found is therefore 62 years of age or less. Breast cancer diagnoses in women under 45 are incredibly uncommon.

The automated breast ultrasound system's high price will hamper the market's growth.

The application of automated breast ultrasound imaging systems has been constrained by severe rules in a number of nations. Additionally, the high cost of automated breast ultrasound systems (ABUS) compared to traditional cancer screening methods is anticipated to restrain market expansion.

COVID-19 Impact Analysis

Infectious disease frequency increased in terms of the severity and rate of dissemination with the beginning of the COVID-19 pandemic. During the early stages of the global pandemic, the number of patients infected with the COVID-19 virus increased. To decrease and control different infection transmission, hospitals adopted emergency protocols as a top priority. This led to a decline in elective procedures that needed ultrasound screening. The use of X-rays, CT scans, and ultrasounds for emergency procedures that needed imaging services increased despite a reduction in elective ultrasound treatments. The adoption of ultrasound equipment for specialized diagnostics, notably for kidneys and lungs, is anticipated to increase due to COVID-19's long-term effects. The number of ultrasound operations for lungs exhibited a rising trend during the early stages of the pandemic.

Segment Analysis

The hospital's segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

ABUS implementation is progressively gaining momentum in more hospitals to meet the patients' diagnostic demands. The demand for ABUS in these healthcare settings will be driven by rising cancer screening test usage among young and middle-aged women. Hospitals are installing ABUS to provide safer diagnostic choices because pregnant women cannot get mammography due to the radiation danger.

Breast cancer surgery involves operating to remove the tumor, which is a crucial part of treatment for the disease. Breast cancer surgery can be used either on its own or in conjunction with other therapies, such as chemotherapy, hormone therapy, targeted therapy, and radiation therapy, administered in a hospital setting under the guidance of a qualified doctor.

Each year, more than 100,000 American women get a mastectomy. Although it is frequently done to treat breast cancer, it is occasionally done to lower the chance of developing breast cancer. Because procedures must be performed in hospitals under the supervision of doctors, the hospital sector drives the market. Compared to general or specialty hospitals, teaching hospitals in several affluent nations have seen a dramatic increase in demand for various treatment modalities. However, the number of new hospitals in developing nations in North America has sharply increased. Imaging modalities typically have their room in new hospitals. Rising competition and rising demand for top-notch medical care are the two main reasons predicted to drive segment expansion.

Geographical Analysis

North America holds the largest market share in the global automated breast ultrasound systems market.

According to the American Society of Cancer, about 281,550 new breast cancer cases will be discovered in women in 2021, and 43,600 women will pass away from the disease. The prevalence of breast cancer is rising, increasing the need for cutting-edge breast imaging equipment and support for efficient therapies. The ABUS market in the U.S. will grow as government campaigns to inform and educate women about breast cancer and the value of screening increase. According to the Breast Cancer Organization, 1 in 8 (or around 13%) American women will eventually develop invasive breast cancer.

In the United States, women are anticipated to receive diagnoses for 287,840 new instances of invasive breast cancer and 51,500 new cases of non-invasive (in situ) breast cancer in 2022. In 2022, it's anticipated that 2,710 new instances of invasive breast cancer will be found in men. About 1 in 833 men may develop breast cancer in their lives. In the U.S., more than 3.8 million women have had breast cancer in the past as of January 2022. Women who have completed treatment and those who are presently receiving it are included. Several foundations in the United States have launched awareness programs, including the Susan Komen Foundation, the National Breast Cancer Foundation, and the American Society of Cancer's National Breast Cancer Awareness (NBCA) month. These will benefit the need for automated breast ultrasonography systems for detecting breast cancer in breast tissue with dense cellularity.

Competitive Landscape

The Automated breast ultrasound systems market is moderately competitive with local and global companies' presence GE Healthcare, Hitachi, Ltd, Koninklijke Philips N.V., Siemens AG , SonoCine Inc, Qview Medical, Hologic Inc, Volpara Solutions Limited, Delphinus Medical Technologies, Inc., Nova Medical Inc and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in December 2022, Koios DS, a software platform powered by artificial intelligence (AI) and shown to effectively diagnose thyroid and breast malignancies in ultrasound tests, has received CE Marking under the EU MDR, according to Koios Medical, a pioneer in the field of cancer diagnostics using ultrasound. The innovative dual-diagnosis method, developed utilizing data from a global network of 55 sites, speeds up interpretation, automates reporting, and shortens the time it takes to administer medication while eliminating unnecessary surgery

General Electric Company.

Overview: E Healthcare, a division of General Electric Company, is a global provider of medical devices that creates, develops, produces, and sells diagnostic imaging and clinical systems, as well as a variety of healthcare IT solutions, products and services for drug discovery, biopharmaceutical production, and cellular technologies. Additionally, GE Healthcare offers services including computerized data management, remote diagnostic and repair services for medical equipment made by the business and others, performance enhancement and performance solutions services, and other services.

Product Portfolio:

Invenia ABUS 2.0: One of the biggest widespread risk factors for getting breast cancer is having thick breasts, which affects about 40% of women. The clinical data supporting the use of ultrasonography to detect tiny, node-negative, invasive tumors that mammography misses is emerging. For dense breast imaging in the screening context, Invenia ABUS 2.0 supplemental imaging is designed.

The global automated breast ultrasound systems market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing technological advancements in automated breast ultrasound systems
      • 4.1.1.2. Rising awareness regarding breast cancer and favorable government initiatives
    • 4.1.2. Restraints:
      • 4.1.2.1. The automated breast ultrasound system's high price
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ultrasound Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 7.1.2. Market Attractiveness Index, By Ultrasound Type
  • 7.2. Doppler ultrasound
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Color Doppler
  • 7.4. Transvaginal ultrasound

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Breast imaging
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Screening

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Diagnostic Imaging Centers
  • 9.4. Diagnostic Laboratories

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Ultrasound Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Products Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. General Healthcare Company
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Hitachi, Ltd
  • 12.3. Koninklijke Philips N.V.
  • 12.4. Siemens AG
  • 12.5. SonoCine Inc
  • 12.6. Qview Medical
  • 12.7. Koios Medical
  • 12.8. Volpara Solutions Limited
  • 12.9. Delphinus Medical Technologies, Inc.
  • 12.10. Nova Medical Inc

LIST NOT EXHAUSTIVE

13. Global Automated breast ultrasound systems Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Application
  • 13.3. Contact Us